Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.

Guardado en:
Detalles Bibliográficos
Autores principales: Yunlong Yang, Yin Zhang, Hideki Iwamoto, Kayoko Hosaka, Takahiro Seki, Patrik Andersson, Sharon Lim, Carina Fischer, Masaki Nakamura, Mitsuhiko Abe, Renhai Cao, Peter Vilhelm Skov, Fang Chen, Xiaoyun Chen, Yongtian Lu, Guohui Nie, Yihai Cao
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/79582752f03043d7b3b6d8145bb72174
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.

Ejemplares similares